Chemoprevention for neurofibromatosis 2: just over the horizon?

por Plotkin, Scott R.
Publicado em 2014

Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis

por Blakeley, Jaishri O., Plotkin, Scott R.
Publicado no Neuro Oncol (2016)

INNV-20. UTILITY OF TELEHEALTH FOR SPECIALTY NEUROFIBROMATOSIS (NF) CARE

por Jordan, Justin, Seijo, Marlon, Merker, Vanessa, Bhadola, Shivkumar, Thalheimer, Raquel, Plotkin, Scott R
Publicado no Neuro Oncol (2018)

Clinical Features of Schwannomatosis: A Retrospective Analysis of 87 Patients

por Merker, Vanessa L., Esparza, Sonia, Smith, Miriam J., Stemmer-Rachamimov, Anat, Plotkin, Scott R.
Publicado em 2012

Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based study

por Terry, Anna R., Barker, Fred G., Leffert, Lisa, Bateman, Brian T., Souter, Irene, Plotkin, Scott R.
Publicado em 2012

Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schw...

por Merker, Vanessa L., Dai, Annie, Radtke, Heather B., Knight, Pamela, Jordan, Justin T., Plotkin, Scott R.
Publicado no BMC Health Serv Res (2018)

Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients

por Plotkin, Scott R., Halpin, Chris, McKenna, Michael J., Loeffler, Jay S., Batchelor, Tracy T., Barker, Fred G.
Publicado em 2010

Effective Provider-Patient Communication of a Rare Disease Diagnosis: A Qualitative Study of People Diagnosed with Schwannomatosis

por Merker, Vanessa L., Plotkin, Scott R., Charns, Martin P., Meterko, Mark, Jordan, Justin T., Elwy, A. Rani
Publicado no Patient Educ Couns (2020)

Expression of SMARCB1 (INI1) mutations in familial schwannomatosis

por Smith, Miriam J., Walker, James A., Shen, Yiping, Stemmer-Rachamimov, Anat, Gusella, James F., Plotkin, Scott R.
Publicado em 2012

mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition

por Beauchamp, Roberta L., Erdin, Serkan, Witt, Luke, Jordan, Justin T., Plotkin, Scott R., Gusella, James F., Ramesh, Vijaya
Publicado no J Biol Chem (2020)

Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome

por Wang, Daphne L., Smith, Kelly B., Esparza, Sonia, Leigh, Fawn A., Muzikansky, Alona, Park, Elyse R., Plotkin, Scott R.
Publicado em 2012

Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth

por James, Marianne F., Lelke, Johanna M., MacCollin, Mia, Plotkin, Scott R., Stemmer-Rachamimov, Anat O., Ramesh, Vijaya, Gusella, James F.
Publicado em 2007

Improvement in patient-reported hearing after treatment with bevacizumab in people with Neurofibromatosis Type 2

por Huang, Victoria, Bergner, Amanda L., Halpin, Chris, Merker, Vanessa L., Sheridan, Monica R., Widemann, Brigitte, Blakeley, Jaishri O., Plotkin, Scott R.
Publicado no Otol Neurotol (2018)

NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth

por James, Marianne F., Han, Sangyeul, Polizzano, Carolyn, Plotkin, Scott R., Manning, Brendan D., Stemmer-Rachamimov, Anat O., Gusella, James F., Ramesh, Vijaya
Publicado em 2009

Achieving consensus for clinical trials: The REiNS International Collaboration

por Plotkin, Scott R., Blakeley, Jaishri O., Dombi, Eva, Fisher, Michael J., Hanemann, C. Oliver, Walsh, Karin S., Wolters, Pamela L., Widemann, Brigitte C.
Publicado em 2013

Conclusions and future directions for the REiNS International Collaboration

por Widemann, Brigitte C., Blakeley, Jaishri O., Dombi, Eva, Fisher, Michael J., Hanemann, Clemens O., Walsh, Karin S., Wolters, Pamela L., Plotkin, Scott R.
Publicado em 2013

Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomics

por Liu, Yunpeng, Jordan, Justin T., Bredella, Miriam A., Erdin, Serkan, Walker, James A., Vangel, Mark, Harris, Gordon J., Plotkin, Scott R., Cai, Wenli
Publicado no Neurology (2020)

The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research

por Radtke, Heather B., Klein-Tasman, Bonita P., Merker, Vanessa L., Knight, Pamela, Ullrich, Nicole J., Jordan, Justin T., Korf, Bruce, Plotkin, Scott R.
Publicado no Orphanet J Rare Dis (2021)

Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors

por Wong, Hon Kit, Lahdenranta, Johanna, Kamoun, Walid S., Chan, Annie W., McClatchey, Andrea I., Plotkin, Scott R., Jain, Rakesh K., di Tomaso, Emmanuelle
Publicado no Cancer Res (2010)

The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities

por Klesse, Laura J., Jordan, Justin T., Radtke, Heather B., Rosser, Tena, Schorry, Elizabeth, Ullrich, Nicole, Viskochil, David, Knight, Pamela, Plotkin, Scott R., Yohay, Kaleb
Publicado no Oncologist (2020)